an AGC kinase of the RSK family that is required for cell growth and G1 cell cycle progression. Is phosphorylated and activated by mTOR in mitogenic pathways downstream of phosphoinositide 3 kinase (PI3K). Phosphorylates the S6 protein of the 40S ribosomal subunit and is involved in translational control of 5' oligopyrimidine tract mRNAs. Activity is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains. Mouse knockout shows symptoms of insulin resistance, and increased insulin senstivity, resulting in protection against diet-induced obesity. Protein expression and activation upregulated in colon adenocarcinoma cell lines. Increased expression in breast cancer correlated with poor survival. Selectively amplified and overexpressed within the 17q23 breast cancer amplicon. Two isoforms produced by alternative initiation have been reported. Note: This description may include information from UniProtKB.
Protein type: Kinase, protein; Protein kinase, AGC; Protein kinase, Ser/Thr (non-receptor); Translation; EC 220.127.116.11; AGC group; RSK family; p70 subfamily
Cellular Component: cytosol; nucleoplasm; presynaptic active zone
Molecular Function: ATP binding; protein binding; protein serine/threonine kinase activity; ribosomal protein S6 kinase activity
Biological Process: actin filament organization; axon guidance; dendrite morphogenesis; determination of adult life span; growth; larval feeding behavior; lipid metabolic process; multicellular organism growth; myoblast fusion; oogenesis; phagocytosis; positive regulation of autophagy; positive regulation of cell growth; positive regulation of cell size; positive regulation of growth; positive regulation of macroautophagy; positive regulation of multicellular organism growth; positive regulation of organ growth; protein amino acid phosphorylation; regulation of cell size; response to DNA damage stimulus; response to nutrient; response to oxidative stress; signal transduction; somatic muscle development; synaptic growth at neuromuscular junction
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.